Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies

Table 4 Multivariate analyses of severe toxicities

Toxicity	Factor	Univariate		Multivariate
		P value	OR	P value	OR	95%CI
Any
	Pre-treatment albumin	0.001	33.600	0.010	26.166	2.194-312.072
	Pre-treatment INR	0.016	9.231	0.048	17.743	1.027-306.461
	Colorectal adenocarcinoma	0.022	4.213	0.070	4.527	0.885-23.155
	Pre-treatment ALP	0.018	12.343	0.187	4.770	0.468-48.651
	Pre-treatment total bilirubin	0.031	13.071	0.327	33.100	0.030-36243.627
	Pre-treatment hemoglobin	0.047	3.467	0.449	1.881	0.366-9.674
	MELD score	0.068	1.364	Excluded1
	Pre-treatment AST	0.032	3.552	Excluded1
Albumin
	Pre-treatment hemoglobin	0.040	9.265	0.025	12.492	1.349-114.011
	Pre-treatment AST	0.039	5.517	0.025	7.404	1.283-42.714
	Pre-treatment total bilirubin	0.047	8.375	0.355	3.349	0.259-43.374
Total bilirubin
	MELD score	0.020	1.625	0.033	1.830	1.050-3.187
	Pre-treatment albumin	0.035	10.138	0.056	9.042	0.941-86.840
	Administered dose	0.099	0.933	0.117	0.922	0.833-1.020
	Pre-treatment INR	0.075	5.583	0.658	1.694	0.165-17.429
	Pre-treatment total bilirubin	0.025	11.500	Excluded1
ALP
	Colorectal adenocarcinoma	0.030	4.552	0.043	5.362	1.058-27.185
	Pre-treatment ALP	0.037	9.237	0.070	15.615	0.803-303.636
	Pre-treatment hemoglobin	0.019	6.581	0.084	4.886	0.809-29.519
	KPS	0.067	0.953	0.150	0.947	0.879-1.020
	Pre-treatment INR	0.049	5.636	0.189	4.903	0.456-52.716
	KPS < 80 vs KPS ≥ 80	0.093	3.314	Excluded1
	Pre-treatment AST	0.050	3.519	Excluded1

¹Variables marked as Excluded were excluded from multivariate analysis due to interdependence. INR: International normalized ratio; ALP: Alkaline phosphatase; MELD: Model for end-stage liver disease; AST: Aspartate aminotransferase; KPS: Karnofsky performance score.